Menu Search
Equities

Inogen Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
6IO:FRA

Inogen Inc

Actions
  • Price (EUR)4.64
  • Today's Change-0.08 / -1.69%
  • Shares traded89.00
  • 1 Year change-54.51%
  • Beta1.7877
Data delayed at least 15 minutes, as of Feb 10 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Inogen, Inc. is a medical technology company offering respiratory products for use in the homecare setting. It supports patient respiratory care by developing, manufacturing, and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its Inogen One and Inogen Rove systems concentrate the air around the patient to offer a source of supplemental oxygen with a battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. Its Inogen One and Inogen Rove systems reduce the patient’s reliance on stationary concentrators and scheduled deliveries of tanks with a finite supply of oxygen. Inogen Connect is a wireless connectivity platform for the Inogen One G4, Inogen One G5, Inogen Rove 4, and Inogen Rove 6, consisting of a front-end mobile application for use by long-term oxygen therapy users. It offers Simeox, which is an airway clearance device.

  • Revenue in USD (TTM)347.03m
  • Net income in USD-25.38m
  • Incorporated2001
  • Employees766.00
  • Location
    Inogen Inc859 WARD DRIVEGOLETA 93111United StatesUSA
  • Phone+1 (805) 562-0500
  • Fax+1 (302) 636-5454
  • Websitehttps://www.inogen.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.